Why the study?
Comprehensive studies comparing DOACs with phenprocoumon, a VKA that accounts for 99% of VKA prescriptions in Germany and often achieves higher time in therapeutic range, are lacking.
Do DOACs compared to phenprocoumon alter the risk of stroke and bleeding in patients with atrial fibrillation?
Population
837,430 patients treated with DOAC or phenprocoumon for stroke prevention in German ambulatory care
Comparison
DOACs vs phenprocoumon
Design
Nationwide retrospective observational propensity score-matched cohort study
Authors
Loading...
DOACs were associated with higher stroke risk than phenprocoumon; leaves open whether real-world differences should alter VKA preference in ambulatory AF.
Do DOACs compared to phenprocoumon alter the risk of stroke and bleeding in patients with atrial fibrillation?
In a large German real-world cohort, DOACs were associated with a higher risk of stroke but a lower risk of bleeding compared to the VKA phenprocoumon.
Paschke et al. (2020) studied this question.